Jack Allen

Gena Wang

Kelly Shi

Salveen Richter

Sebastiaan van der Schoot

Yanan Zhu

Hartaj Singh

Huidong Wang

Silvan Tuerkcan

- CLLS is advancing its **Lasmarcel (CD22-targeted therapy)** into a Phase 2 pivotal program, targeting patients aged **12 to 50** with a recommended dose of **five million cells per kilogram**.  **[0001627281_2188080_4]** **[0001627281_2188080_7]** 
- The company has established fully **internalized manufacturing** for Lasmarcel, including its supply chain and logistics, with facilities in Europe and the United States, positioning it for commercial readiness and cost control.  **[0001627281_2188080_0]** 
- CLLS projects potential peak gross sales for Lasmarcel of up to **$700 million** in the US, EU4, and UK for the initial third-line plus indication by 2035, with a potential increase to **$1.3 billion** with future label expansion.  **[0001627281_2188080_14]** **[0001627281_2188080_15]** 
- The company anticipates submitting **two Biologics License Applications (BLAs)** for Lasmarcel and alemtuzumab in **2028**, with enrollment completion expected by Q3 2027 and primary analysis in Q1 2028.  **[0001627281_2188080_8]**

CLLS Outlines Lasmarcel Development and Commercial Strategy

- Cellectis is hosting an R&D Day today, **October 16, 2025**, in New York City.  **[1627281_e0c8af6bc5284d7abd90454a8b330e80_0]** 
- The event will feature the **full Phase 1 dataset** and outline the **pivotal Phase 2 trial design** and commercial opportunity for **lasme-cel (UCART22) in r/r B-ALL**.  **[1627281_e0c8af6bc5284d7abd90454a8b330e80_0]** 
- Cellectis is a clinical-stage biotechnology company that utilizes its gene editing platform to develop life-saving cell and gene therapies, focusing on allogeneic CAR T immunotherapies.  **[1627281_e0c8af6bc5284d7abd90454a8b330e80_1]**

Cellectis Hosts R&D Day Showcasing Lasme-cel Data and Phase 2 Strategy

- Cellectis is hosting an **R&D Day** today, **October 16, 2025**, in New York City to showcase pipeline progress and long-term value drivers.  **[1627281_0001171843-25-006470_exh_991.htm:0]** 
- The event will feature the **full Phase 1 dataset** and outline the **pivotal Phase 2 trial design** for **lasme-cel (UCART22)** in r/r B-ALL.  **[1627281_0001171843-25-006470_exh_991.htm:0]** 
- Cellectis will also present the **commercial opportunity** for lasme-cel in r/r B-ALL.  **[1627281_0001171843-25-006470_exh_991.htm:0]**

Cellectis hosts R&D Day to showcase pipeline progress and lasme-cel data

Cellectis (CLLS)